Ford Says Its Quality Is Improving; Why Is This Number Going in the Wrong Direction?
The auto industry has gradually experienced more problems with new vehicles.
Ford's quality improvement will take time to see as new vehicles replace old models.
10 stocks we like better than Ford Motor Company ›
One of the big knocks against Ford Motor Company (NYSE: F) over the past few years has been its recalls, and the sometimes higher warranty costs associated with them. When automakers such as Ford have a large recall, which sometimes requires customers to bring vehicles in for service, it can ring up a hefty bill on its financials.
In the past, the warranty costs spiked enough to hinder the company's earnings. Ford's stance has been that it's made substantial improvements on quality, but if that's the case, why isn't it scoring better in J.D. Power's 2025 Initial Quality Study? Let's dig in.
J.D. Power's Initial Quality Study (IQS) is in its 39th year and collects responses from over 90,000 customers of 2025 new vehicle models, who were then surveyed after 90 days of ownership. The study's goal is to gauge how many problems per 100 vehicles, sorted by brand. It's a simple way to evaluate the quality of new vehicles, with the lower the score, the better.
And this year's winner is, drum roll: Lexus (owned by Toyota)! Lexus was the highest-ranking brand overall in the study, with a score of 166 PP100. For premium brands, Lexus was followed by Jaguar and Genesis, with respective scores of 175 PP100 and 183 PP100.
For mass-market brands, Nissan might have shocked a few investors in ranking highest, or scoring lowest, at 169 PP100. Hyundai and Chevrolet (part of General Motors) rounded out the top three for mass-market brands with scores of 173 PP100 and 178 PP100, respectively.
Now, gathering all of a parent company's brands under their respective umbrellas -- for example, General Motors owns brands Cadillac, Chevrolet, Buick, and GMC -- the OEM with the most model-level awards was GM with five, followed by Ford with four, and Honda with three.
Now let's take a closer look at Ford and see if we can extrapolate any IQS data for perhaps a preview of future issues and potential recalls.
As you probably noted in the graphic, Ford checked in just below industry average. That's respectable and raises no red flags, but it's worth glancing through some history to better understand trends. Ford's score of 193 PP100 in 2025 was noticeably worse than last year's score of 178 PP100, which was good enough to rank in the top third of all brands.
Taking it a little bit further, let's rewind the clock to 2020, when Ford scored an even better 174 PP100. In 2015, Ford scored a far better 107 PP100. This brings up an important question: Is Ford's vehicle quality really improving? And if it isn't, should investors expect rising warranty costs and hindered earnings?
Not so fast!
There are a couple of important factors to consider before jumping to conclusions regarding Ford's trending scores. First, the industry average has moved in similar a similar trend line. That's because over the past decade, vehicles have grown far more complex in terms of innovation, driver assistance systems, and infotainment services, among others. As those new technologies debut, rarely does it happen without initial problems that eventually get worked out over time.
Second, we also have to consider the severity of these problems. J.D. Power noted that the infotainment category remains the most problematic vehicle category. In fact, half of the top problems industrywide remain infotainment issues.
Another consumer issue: cupholder size. That's right, one of the biggest and most reoccurring complaints is that the size of cupholders often doesn't fit reusable containers.
Ford won't miss earnings this quarter because of infotainment system or cupholder size recalls. The J.D. Power study scores aren't likely correlated to recalls, or accompanying warranty costs, because it's looking for initial problems within the first 90 days -- not a time frame there's likely to be a major repair/recall needed.
Does this study have value? Absolutely. It's a wonderful resource to gauge consumer feedback on new vehicle models that will become the bloodline of automakers. But can we take Ford's worsening scores to mean that its vehicle quality isn't improving, at least the important things (looking at you, cupholders)?
No, not in my opinion. It takes time for Ford's more recent push on quality to work through the process, and for newer cars to replace older, more problematic models.
At the end of the day, while investors would love to see Ford improve year after year and even overtake Lexus at the top, these scores don't raise any real red flags when it comes to potential recalls or potential earnings hits.
Before you buy stock in Ford Motor Company, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Ford Motor Company wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!*
Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of July 7, 2025
Daniel Miller has positions in Ford Motor Company and General Motors. The Motley Fool recommends General Motors. The Motley Fool has a disclosure policy.
Ford Says Its Quality Is Improving; Why Is This Number Going in the Wrong Direction? was originally published by The Motley Fool
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Inspire Medical Systems, UFP Technologies, Globus Medical, Neogen, and Dentsply Sirona Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Medical Devices & Supplies - Specialty company Inspire Medical Systems (NYSE:INSP) jumped 3%. Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it's free. Drug Development Inputs & Services company UFP Technologies (NASDAQ:UFPT) jumped 3.5%. Is now the time to buy UFP Technologies? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Globus Medical (NYSE:GMED) jumped 3%. Is now the time to buy Globus Medical? Access our full analysis report here, it's free. Medical Devices & Supplies - Diversified company Neogen (NASDAQ:NEOG) jumped 3.4%. Is now the time to buy Neogen? Access our full analysis report here, it's free. Dental Equipment & Technology company Dentsply Sirona (NASDAQ:XRAY) jumped 3.1%. Is now the time to buy Dentsply Sirona? Access our full analysis report here, it's free. Zooming In On UFP Technologies (UFPT) UFP Technologies's shares are very volatile and have had 24 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 7 days ago when the stock gained 11.9% on the news that the company posted record second-quarter results and beat analyst profit expectations. The medical products company reported a 37.2% surge in sales to $151.2 million compared to the same period last year. Its adjusted earnings per share reached $2.50, which surpassed Wall Street's consensus estimate of $2.25. This strong performance was primarily driven by a 46% jump in its MedTech business, fueled by demand in areas like robotic-assisted surgery. However, the results included a 20% decline in its Advanced Components division, and the company noted increased labor costs pressured margins. UFP Technologies is down 10.2% since the beginning of the year, and at $221.03 per share, it is trading 38.3% below its 52-week high of $358.42 from September 2024. Investors who bought $1,000 worth of UFP Technologies's shares 5 years ago would now be looking at an investment worth $5,057. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
21 minutes ago
- Yahoo
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Therapeutics company Moderna (NASDAQ:MRNA) jumped 3.1%. Is now the time to buy Moderna? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Teleflex (NYSE:TFX) jumped 4.1%. Is now the time to buy Teleflex? Access our full analysis report here, it's free. Dental Equipment & Technology company Envista (NYSE:NVST) jumped 3.1%. Is now the time to buy Envista? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Enovis (NYSE:ENOV) jumped 3.5%. Is now the time to buy Enovis? Access our full analysis report here, it's free. Health Insurance Providers company UnitedHealth (NYSE:UNH) jumped 3%. Is now the time to buy UnitedHealth? Access our full analysis report here, it's free. Zooming In On Teleflex (TFX) Teleflex's shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock dropped 22.9% on the news that the company reported disappointing fourth-quarter results, with revenue missing expectations by a significant margin. On a constant currency basis, revenue increased 3.2%, but this still fell short of Wall Street's estimates. Weak demand in Interventional Urology wiped out gains in the Interventional and Surgical units. Looking ahead, the company's 2025 revenue guidance implies little to no growth, with management projecting revenue to be flat to slightly up. Overall, this was a weaker quarter, weighed down by sluggish growth, margin pressures, and a subdued outlook. Teleflex is down 32.8% since the beginning of the year, and at $120.33 per share, it is trading 51.3% below its 52-week high of $247.32 from September 2024. Investors who bought $1,000 worth of Teleflex's shares 5 years ago would now be looking at an investment worth $320.02. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
21 minutes ago
- Yahoo
Expedia Group Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Expedia Group's Fair Values from the Community and select yours Expedia Group (NASDAQ:EXPE) Second Quarter 2025 Results Key Financial Results Revenue: US$3.79b (up 6.4% from 2Q 2024). Net income: US$330.0m (down 14% from 2Q 2024). Profit margin: 8.7% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: US$2.61 (down from US$2.93 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Expedia Group Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 25%. Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Hospitality industry in the US. Performance of the American Hospitality industry. The company's shares are up 4.1% from a week ago. Balance Sheet Analysis While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Expedia Group's balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data